The Top Line · Fierce Life Sciences

How physiology powers biotech innovation (Sponsored)

·13 min·1 clip

Sue Bodine reveals that 'most costly failures happen because therapies behave differently in whole organisms than in reductionist models,' citing heart side effects from kidney drugs.

Host Chris Hayden interviews Sue Bodine, president-elect of the American Physiological Society, about the foundational role of physiology in biotech innovation. They discuss how physiology connects basic science to clinical outcomes, enables wearable technology and AI tools, prevents costly drug failures, and faces critical funding challenges that threaten biomedical progress.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Top Line